Rotavirus Infections - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rotavirus Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Rotavirus Infections - Pipeline Review, H2 2015', provides an overview of the Rotavirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rotavirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Rotavirus Infections - Overview 8
Pipeline Products for Rotavirus Infections - Comparative Analysis 9
Rotavirus Infections - Therapeutics under Development by Companies 10
Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 11
Rotavirus Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Rotavirus Infections - Products under Development by Companies 15
Rotavirus Infections - Products under Investigation by Universities/Institutes 16
Rotavirus Infections - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Biological E. Limited 18
CureVac GmbH 19
Medicago Inc. 20
Nanotherapeutics, Inc. 21
SEEK Group 22
Serum Institute of India Limited 23
Shantha Biotechnics Limited 24
Sinovac Biotech Ltd. 25
Takeda Pharmaceutical Company Limited 26
Rotavirus Infections - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Antibody for Rotavirus Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Oligonucleotide for Rotavirus Infection - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rotavirus (pentavalent) vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rotavirus (tetravalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rotavirus [serotypes G1, G2, G3, G4] (tetravalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rotavirus vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
rotavirus vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rotavirus vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rotavirus vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rotavirus vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rotavirus virus like particle vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RV-625 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Rotavirus Infections - Recent Pipeline Updates 50
Rotavirus Infections - Dormant Projects 51
Rotavirus Infections - Product Development Milestones 52
Featured News & Press Releases 52
Oct 14, 2014: Shantha`s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India 52
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate 52
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus 53
Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana 54
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan 54
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Rotavirus Infections, H2 2015 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 17
Rotavirus Infections - Pipeline by Biological E. Limited, H2 2015 18
Rotavirus Infections - Pipeline by CureVac GmbH, H2 2015 19
Rotavirus Infections - Pipeline by Medicago Inc., H2 2015 20
Rotavirus Infections - Pipeline by Nanotherapeutics, Inc., H2 2015 21
Rotavirus Infections - Pipeline by SEEK Group, H2 2015 22
Rotavirus Infections - Pipeline by Serum Institute of India Limited, H2 2015 23
Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H2 2015 24
Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H2 2015 25
Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Number of Products by Stage and Target, H2 2015 29
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Rotavirus Infections Therapeutics - Recent Pipeline Updates, H2 2015 50
Rotavirus Infections - Dormant Projects, H2 2015 51